Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial +++

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00031-3/fulltext?dgcid=hubspot_update_feature_updatealerts_laninf&utm_campaign=update-laninf&utm_medium=email&_hsenc=p2ANqtz-8E66_u5XILjwghE2dxUUIaGpcu3vblVlUIuVfkbxOOzDfYPdPq6pHSviUwY3ch8O14TW3EpIvLOLCXGQP2dNK_1SFTKQ&_hsmi=374526042&utm_content=374288840&utm_source=hs_email Editorial p827 A commission on vector-borne infections The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/issue/vol25no8/PIIS1473-3099(25)X0008-6 Efficacy and safety of individualised versus standard 10-day antibiotic treatment in children with febrile urinary tract infection (INDI-UTI): a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial in Denmark https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00075-1/abstract?utm_campaign=update-laninf&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laninf&_hsenc=p2ANqtz--lnLWOPITeF2NStUBuleeVLU_yQmAXB25PIy1Fq8QRd4-oe-Eo9ATpT_V9edqVIJhpq11BwppIp3Cgmm2qQsSTeeLIbA&_hsmi=374526042&utm_content=374288840&utm_source=hs_email